Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: No significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 5, 1999, Pages 741-743

  Schroder C P ^a   De Vries, E G E ^a   Mulder, N H ^a   Willemse, P H B ^a   Sleijfer, D T ^a   Hospers, G A P ^a   Van Der Graaf, W T A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GROWTH FACTOR; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FEVER; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LEUKOPENIA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AMPHOTERICIN B; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CIPROFLOXACIN; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; FEVER; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LENGTH OF STAY; LEUKOPENIA; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NETHERLANDS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 0344483875     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.5.741     Document Type: Article

References (8)

1. O'Reilly, S. E., Gelmon, K. A., Onetto, N., Parente, J., Rubinger, M., Page, R. A. et al. (1993). Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin and fluorouracil. Journal of Clinical Oncology 11, 2411-16.
2. Rusthoven, J. J., De Vries, E. G. E., Dale, D. C., Piccart, M., Glaspy, J. & Hamilton, A. (1997). Consensus on the use of neutrophil-stimulating haematopoietic growth factors in clinical practice: an international viewpoint. International Journal of Antimicrobial Agents 8, 263-75.
3. Hartmann, L. C., Tschetter, L. K., Habermann, T. M., Ebbert, L. P., Johnson, P. S., Mailliard, J. A. et al. (1997). Granulocyte colony stimulating factor in severe chemotherapy-induced afebrile neutropenia. New England Journal of Medicine 336, 1776-80.
4. Klastersky, J. (1996). Prevention of infection in neutropenic cancer patients. Current Opinion in Oncology 8, 270-8.
5. World Health Organization. (1979). Handbook for Reporting Results of Cancer Treatment, pp. 15-22. WHO, Geneva.
6. American Society for Clinical Oncology. (1996). Update of recommendations for the use of haematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. Journal of Clinical Oncology 14, 1957-60.
7. Vellenga, E., Uyl-de Groot, C. A., De Wit, R., Keizer, H. J., Löwenberg, B., ten Haaft, M. A. et al. (1996). Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology 14, 619-27.
8. Carlson, J. W., Fowler, J. M., Saltzman, A. K., Carter, J. R., Chen, M. D., Mitchell, S. K. et al. (1994). Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecologic Oncology 55, 415-20.